3 Stocks Dragging The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 37 points (-0.2%) at 16,809 as of Friday, June 27, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,843 issues advancing vs. 1,114 declining with 177 unchanged.

The Health Care sector currently sits up 0.2% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include Alexion Pharmaceuticals ( ALXN), down 1.5%, WellPoint ( WLP), down 0.9%, UnitedHealth Group ( UNH), down 0.7%, Aetna ( AET), down 0.7% and Vertex Pharmaceuticals ( VRTX), down 0.7%. Top gainers within the sector include Taro Pharmaceutical Industries ( TARO), up 13.9%, Intuitive Surgical ( ISRG), up 2.7%, Fresenius Medical Care AG & Co. KGaA ( FMS), up 1.6%, Endo International ( ENDP), up 1.3% and Valeant Pharmaceuticals International ( VRX), up 1.3%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Regeneron Pharmaceuticals is down $7.72 (-2.8%) to $272.08 on heavy volume. Thus far, 854,533 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 863,400 shares. The stock has ranged in price between $269.50-$281.95 after having opened the day at $280.00 as compared to the previous trading day's close of $279.80.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $27.8 billion and is part of the drugs industry. Shares are up 1.7% year-to-date as of the close of trading on Thursday. Currently there are 6 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and weak operating cash flow. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Mylan ( MYL) is down $0.53 (-1.0%) to $51.34 on light volume. Thus far, 1.2 million shares of Mylan exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $51.30-$52.12 after having opened the day at $51.75 as compared to the previous trading day's close of $51.87.

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. Mylan has a market cap of $19.3 billion and is part of the drugs industry. Shares are up 19.5% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Mylan a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Mylan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Mylan Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Amgen ( AMGN) is down $1.19 (-1.0%) to $117.95 on light volume. Thus far, 1.1 million shares of Amgen exchanged hands as compared to its average daily volume of 3.6 million shares. The stock has ranged in price between $117.50-$119.50 after having opened the day at $119.47 as compared to the previous trading day's close of $119.14.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $90.4 billion and is part of the drugs industry. Shares are up 4.4% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC